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Original ArticleA Rapamycin-Based GMP-Compatible Process
for the Isolation and Expansion of Regulatory T
Cells for Clinical Trials
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Andrew Hope,1 Christopher Fisher,1 Rachel Hilton,2 David Game,2 Paul Harden,3 Andrew Bushell,4 KathrynWood,4
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Hospital, Guy’s and St. Thomas NHS Foundation Trust; 3Oxford Transplant Centre, Oxford, UK; 4Transplantation Research Immunology Group, Nufﬁeld Department
of Surgical Sciences, University of Oxford, Oxford, UKThe concept of regulatory T cell (Treg)-based immunotherapy
has enormous potential for facilitating tolerance in autoimmu-
nity and transplantation. Clinical translation of Treg cell ther-
apy requires production processes that satisfy the rigors of
GoodManufacturing Practice (GMP) standards. In this regard,
we report our ﬁndings on the implementation of a robust GMP
compliant process for the ex vivo expansion of clinical grade
Tregs, demonstrating the feasibility of this developed process
for the manufacture of a ﬁnal product for clinical application.
This Treg isolation procedure ensured the selection of a pure
Treg population that underwent a 300-fold expansion after
36 days of culture, while maintaining a purity of more than
75% CD4+CD25+FOXP3+ cells and a suppressive function of
above 80%. Furthermore, we report the successful cryopreser-
vation of the ﬁnal product, demonstrating the maintenance
of phenotype and function. The process outlined in this manu-
script has been implemented in the ONE study, a multicenter
phase I/IIa clinical trial in which cellular therapy is investigated
in renal transplantation.Received 31 July 2017; accepted 16 January 2018;
https://doi.org/10.1016/j.omtm.2018.01.006.
5These authors contributed equally to this work.
Correspondence: Niloufar Saﬁnia, Division of Transplantation, Immunology and
Mucosal Biology, King’s College London, London, UK.
E-mail: niloufar_saﬁnia@yahoo.comINTRODUCTION
Naturally occurring, thymus-derived, CD4+CD25+FOXP3+ regula-
tory T cells (Tregs) play a critical role in various immunological pro-
cesses, favoring homeostasis. These cells are responsible for the
induction and maintenance of peripheral tolerance to both self and
foreign antigens.
Research in animal models has demonstrated that the adoptive
transfer of murine Tregs can be used to treat several autoimmune
diseases, including type I diabetes,1 multiple sclerosis,2 and rheuma-
toid arthritis,3 in animal models. The pathophysiology of these
diseases in man proposes that they have arisen, in part, due to a
deﬁciency in Treg number and/or functional defects.4,5 In the
context of transplantation, we have demonstrated that in vitro
expanded murine Tregs can induce indeﬁnite heart allograft survival
and skin graft prolongation,6–9 with further studies reporting the198 Molecular Therapy: Methods & Clinical Development Vol. 8 March
This is an open access article under the CC BY license (http://creatiprevention of graft-versus-host disease (GVHD) following bone
marrow transplantation.10,11
A key breakthrough in the translational potential of Treg cell therapy
was the demonstration that human Tregs could be successfully iso-
lated and expanded ex vivo while maintaining immunoregulatory
function. Moreover, we have also demonstrated that the adoptive
transfer of polyclonally expanded human Tregs protects from alloim-
mune-mediated human vessel and skin pathology and induces
increased survival of transplanted islets in humanized mouse models
of transplantation.12–17
More importantly, the isolation and expansion of Good
Manufacturing Practice (GMP)-compliant Tregs has enabled the
application of these cells in the clinic, leading to Treg adoptive
transfer in phase I clinical trials of bone marrow transplantation
and type I diabetes.18–21 Data from such trials have not only proven
to be invaluable in establishing the safety and efﬁcacy of Treg-based
therapy, but has encouraged the broader application of such
cell therapy, including trials in the setting of solid organ transplan-
tation. One such trial is the recently completed ONE study
(NCT02129881), a multicenter phase I/II study funded by the Euro-
pean Union FP7 program investigating the safety and potential ef-
ﬁcacy of infusing ex vivo expanded Tregs, and other regulatory cells,
in the context of kidney transplantation.
The success of a clinical trial such as the ONE study requires a
highly reproducible process for the sustained manufacture of autol-
ogous patient-derived Tregs. To date, processes for the isolation of
autologous Tregs have predominantly used immunomagnetic bead2018 ª 2018 The Authors.
vecommons.org/licenses/by/4.0/).
Figure 1. Comparison of Isolation Strategies,
Protocol A, CD25 Enrichment, and Protocol B, CD8
Depletion and CD25 Enrichment, on the Purity of
Treg Lines
(A) Representative plots depicting the percentage of
contaminatingCD8+ cells in cultures on isolation (fresh) and
after 36 days of expansion in the presence and absence of
rapamycin (rapa versus untreated, respectively). (B) Influ-
ence of isolation strategy on % of CD8+ cells. Protocol
A shows that at final harvest (day 36), the number of CD8+
cells significantly increases in both untreated and rapa-
treated lines as compared to freshly isolated. Protocol
B shows no difference between different treatments, and
the % of CD8+ cells decreases in culture in both the pres-
enceandabsenceof rapamycin. (C)Representative plotsof
% CD4+CD25+FOXP3+ cells in cultures on isolation (fresh)
and after 36 days of expansion in the presence and
absenceof rapamycin (rapaversusuntreated, respectively).
(D) Therewasnodifference in the%ofCD4+CD25+FOXP3+
cells between protocol B or protocol A nor between cells
cultured in the presence or absence of rapamycin. Data
represent the average ± SD of 3 independent experiments.
Statistical analysis was performed using 1-way ANOVA,
and where there was a significant difference, this is indi-
cated. *p < 0.05; **p < 0.01; ***p < 0.001.
www.moleculartherapy.orgisolation, offering a versatile means of cell selection in accordance
with GMP processes. Despite its relative merits, the major drawback
with this technique is the inability to select cells based on stricter
criteria (CD25hi) or multiple parameters (e.g., low expression of
CD127) in contrast with ﬂuorescence activated cell sorting
(FACS), which is still not available in a closed-system GMP-
compliant manner in the UK. One of the drawbacks of the bead-iso-
lated system is that the selected Treg population may contain
activated effector T cells, posing a concern in the context of subse-
quent expansion and clinical application, whereby the effectors may
have the potential to proliferate uncontrollably and, once injected,
instigate graft damage.
In order to reduce the risk that Treg preparations are contaminated
with pro-inﬂammatory cells, many researchers have sought to estab-
lish GMP-compatible processes to improve the purity of Treg prepa-
rations for clinical application. In this regard, it has been shown that
supplementing Treg cultures with the immunosuppressant rapamy-
cin, a mechanistic target of rapamycin (mTOR) kinase inhibitor, re-
sults in the selective expansion of Tregs.22–24
In this study, we have established a rapamycin-based GMP-compat-
ible process for the manufacture of GMP-compliant Tregs for cell
therapy application. We have compared different reagents and con-
ditions for the enrichment and culture of Tregs and present the vali-
dation of our process in the Biomedical Research Centre (BRC)
GMP Facility at Guy’s Hospital, King’s College London. We demon-
strated that by employing a rapamycin-based process, a phenotypi-
cally stable population of Tregs that maintain their suppressive
function can be expanded and used clinically in the setting of the
ONE study.MoleculRESULTS
CD8+ T Cell Depletion Is Advantageous for Obtaining a Pure and
Functional Treg Population
A key component of Treg cellular therapy is the ability to isolate and
expand a pure population of Tregs for clinical use. In order to develop
a standardized, reproducible, isolation strategy, we compared a one-
step positive selection of CD25+ cells (anti-CD25-beads, Miltenyi
Biotec) (protocol A) with a double-step strategy in which peripheral
blood mononuclear cells (PBMCs) were ﬁrst depleted of CD8+ T cells
(anti-CD8 beads, Miltenyi Biotec) and subsequently enriched for
CD25+ T cells (anti-CD25 beads, Miltenyi Biotec) (protocol B).
Freshly isolated Tregs, prepared in accordance with these two separate
processes, were characterized by surface staining forCD8,CD4, CD25,
and intracellular staining for the transcription factor FOXP3. It was no
surprise that adopting protocol B resulted in a lower percentage of
CD8+ cells on isolation in comparison with protocol A (Figures 1A
and 1B). However, there was no difference in the percentage of freshly
isolated CD25+ and FOXP3+ T cells using protocol B, 91.80 ± 4.52, as
compared to protocol A, 90.23 ± 4.91, p = 0.71 (Figures 1C and 1D).
The concept of Treg therapy is based on the expectation that the pu-
rity of the Treg population is maintained throughout ex vivo expan-
sion, with no contaminants in the ﬁnal Treg preparation. In order to
investigate the inﬂuence of CD8 depletion and the effects of this im-
purity on the expanded Tregs, with respect to their expansion proﬁle,
phenotype, and suppressive function, freshly isolated Tregs from pro-
tocol A and protocol B were cultured for 36 days in X-vivo 15, supple-
mented with 5% human serum in the presence of interleukin-2 (IL-2)
(500 IU/mL). Furthermore, and based on previous observations
by our group and others, which highlight the importance ofar Therapy: Methods & Clinical Development Vol. 8 March 2018 199
Figure 2. The Effect of Protocol A and Protocol B on the Expansion and
Function of Treg Lines
(A) Tregs were expanded by stimulation with anti-CD3/CD28 beads and expanded
for 36 days with IL-2 in the presence (rapa) or absence (untreated) of rapamycin.
There was no difference in the fold expansion of Tregs between the different
isolation strategies (protocol A and protocol B) or culture conditions. (B) The sup-
pressive function of freshly isolated Tregs and expanded Treg lines. Suppressive
ability of Tregs was measured as a decrease of proliferation of effector T cells in the
presence of different concentrations of Tregs (Treg:Teff 1:1 and 1:10). Data
represent the percentage Treg suppression at a Treg:Teff ratio of 1:1. Data repre-
sent mean ± SD of 3 independent experiments. Statistical analysis was performed
using 1-way ANOVA and revealed no significant difference.
Molecular Therapy: Methods & Clinical Developmentsupplementing cultures with rapamycin,23,24 the addition of this
immunosuppressant to the cultures and the inﬂuence of this on the
parameters described were also assessed.
The use of protocol A resulted in an increased percentage of CD8+
T cells by ﬁnal harvest, with a more pronounced increase in the rapa-
mycin-treated cultures as compared to the untreated cultures
(p = 0.0002), supporting previous reports of the expansion in vivo
of murine CD8+ T cells in the presence of rapamycin (Figures 1A
and 1B).25 In contrast, the use of protocol B ensured that the percent-
age of CD8+ cells was less than 5% at the end of the 36-day expansion
period (Figures 1A and 1B). However, there were no signiﬁcant differ-
ences in the percentage of CD25+ and FOXP3+ Tregs between the two
processes after expansion, and this was not inﬂuenced by the presence
of rapamycin (Figures 1C and 1D). In addition, in keeping with pre-
vious studies,26 the presence of rapamycin in the culture led to a
higher expression of the CD25 molecule (Figures 1A and 1C).
Treg lines generated, using protocol A and protocol B as isolation
strategies, were also assessed according to their in vitro expansion200 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchcapacity and functional activity (Figures 2A and 2B). The addition
of rapamycin to the cultures did not affect either the rate or fold
of Treg expansion in either process (p = 0.33, Figure 2A). We
next compared the regulatory function of each Treg line by
measuring their ability to suppress the proliferation of co-cultured
carboxyﬂuorescein succinimidyl ester (CFSE)-labeled T effectors
stimulated with anti-CD3/CD28 beads during a 5-day culture
period. Similar to the expansion proﬁle, there was no signiﬁcant
difference observed between the two protocols (Figure 2B). When
further characterizing the Tregs after expansion, no differences
were detected between the two processes in the percentages of Tregs
expressing the homing receptors CD62L, CCR4, and CLA in the
presence or absence of rapamycin. However, the percentage of Tregs
expressing CD27 molecules was increased when the Tregs were iso-
lated and expanded using protocol B (data not shown). This marker
on Tregs has been associated with increased Treg suppressive
function.24,27
At this point, it was concluded that for Treg isolation, incorpo-
ration of a CD8 depletion step was advantageous over isolation
based on CD25-positive selection alone. This isolation strategy
reduced the presence of a potentially alloreactive CD8 popu-
lation, increasing the suitability of the ﬁnal product for clinical
application. In addition, supplementation of rapamycin to the
cultures resulted in the expansion of a pure population of
Tregs with increased suppressive function. As such, the remaining
experiments were conducted by adopting protocol B as isolation
strategy with the addition of rapamycin to cultures, during
expansion.
Depletion of CD8+ T Cells and Enrichment of CD25+ Cells Gives
Rise to 80% of FOXP3+ Cells
In order to test the efﬁciency of the isolation strategy and the
reproducibility of the data, we generated 25 Treg lines, isolated
via CD8 depletion and CD25 enrichment. The mean purity
of the freshly isolated lines was 76.9% ± 12.3%, as assessed
by surface staining for CD4, CD25, and intracellular staining
for FOXP3 (Figure 3A). Treg immunotherapy is dependent on
the expansion of a highly pure population of Tregs for cell
therapy application. In this regard, the purity of the 25 lines was
assessed throughout the 36 days of cultures. We show a signiﬁcant
increase in the purity of rapamycin-treated Tregs when compared
to freshly isolated Tregs, with an average purity of Tregs cultured
in the presence of rapamycin of 91.6% ± 9.3%, p = 0.0017 (Fig-
ure 3A). These results conﬁrm that adopting protocol B for Treg
isolation results in a consistently pure population of expanded
Treg cells.
80% of the Treg Lines Expanded In Vitro Reached Numbers
Sufficient for Clinical Application
Considering that Tregs only comprise around 1%–3% of total pe-
ripheral blood CD4+ T cells in humans, and with animal studies
showing that Tregs in such paucity will not suppress immune re-
sponses, we focused on the development of a strategy centered on2018
AC D
B Figure 3. Purity, Expansion, and Phenotypic
Characterization of Tregs on Isolation and
Expansion
Tregs isolated in accordance with protocol B, stimulated
with anti-CD3/CD28 beads, and expanded for 36 days
with IL-2 in the presence (rapa) or absence (untreated) of
rapamycin. (A) CD4+CD25+FOXP3+ expression of freshly
isolated cells and expanded Treg lines. (B) Treg fold
expansion by day 36 of culture. Rapa-treated and un-
treated cultures exhibited similar expansion profiles.
(C) Total Treg numbers post expansion. (D) Expression of
regulatory markers and homing receptor expression on
CD4+CD25+FOXP3+ cells throughout culture. S- stimu-
lation: S1, day 0; S2, day 12; S3, day 24; and final
harvest, day 36. Data represent the mean ± SD of 25
independent experiments. Statistical analysis was per-
formed using 1-way ANOVA, and where there was a
significant difference, this is indicated. *p < 0.05; **p <
0.01; ***p < 0.001.
www.moleculartherapy.orgthe large-scale expansion of these cells.11 Here, we show the expan-
sion rates for all the Treg lines at ﬁnal harvest, with an average
expansion rate for untreated Treg lines of 4,413 ± 1,285 and
6,059 ± 2,409 for rapamycin-treated lines (Figure 3B). In support
of the robustness of the process, we clearly showed that even
when starting with only 1  106 Tregs, and not the total number
of Tregs isolated, 80% of the lines treated with rapamycin reached
the maximum dose of Tregs that is planned for the ONE study
(10  106/kg) (Figure 3C).
Treg Lines Express Markers that Characterize Functional Tregs
It is well known that Tregs are a heterogeneous population of cells
expressing different surface molecules associated with their regula-
tory function and migratory ability. In this regard, the expression
of CD62L, CD27, CD39, CTLA4, CLA, CCR4, and B7 by Tregs
was assessed after 36 days of expansion (Figure 3D). Previous re-
ports have highlighted that the expression of CD27 and CD62L cor-
relates with high Treg suppressive ability both in vitro and
in vivo.15,16,28
A high percentage of freshly isolated cells expressed CD62L, 69.06 ±
4.81, and CD27, 85.28 ± 2.89, which was maintained by ﬁnal harvest
in the presence of rapamycin, 65.9 ± 5.71, p = 0.703, and 59.11 ± 5.87,
p = 0.002, respectively. However, a lower proportion of Tregs express-
ing these markers at ﬁnal harvest was found in the untreated cultures
as compared to rapamycin-treated cells, CD62L, p = 0.001, and CD27,
p = 0.003, further supporting the crucial role of rapamycin in the
maintenance of these markers during Treg expansion, as previously
published by us.24
With regards to the expression of the ectonucleotidase CD39, it has
been reported that the expression of CD39 on FOXP3+ cells de-
notes a stable Treg phenotype, with the FOXP3+CD39 Treg sub-
set associated with the production of IL-17, although preserving
their suppressive function.29 In addition, CD39 has been describedMoleculas a marker of Treg maturation and activation. In support of this,
during the 36-day expansion, there was an increased percentage of
cells expressing CD39 in both untreated, p = 9.01e8, and rapamy-
cin-treated Treg lines, p = 0.001, as compared to freshly isolated
Tregs.
Rapamycin Ensures the Expansion of Functional and Stable
Tregs, which Do Not Convert to Th17 Cells in the Presence of
Pro-inflammatory Cytokines
In order to expand Tregs for clinical application, it is imperative to
ensure that Tregs retain their suppressive function during ex vivo
expansion. In this regard, following the 36-day expansion, Tregs
were assessed for their suppressive capacity using a CFSE dilution
assay. Figure 4A depicts a representative suppression assay, with
freshly isolated Tregs before and after the 36-day expansion in the
presence and absence of rapamycin. Tregs cultured in the presence
of rapamycin showed an increased suppressive ability, which was
also maintained at the different Treg:Teff dilutions in contrast to
the untreated cultures. Interestingly, the rapamycin-treated Tregs
also exhibited an increased suppressive function as compared to
freshly isolated cells.
The results obtained from the 25 freshly isolated and expanded Treg
lines at a 1:1 Treg:Teff ratio is represented in Figure 4B. After 36 days
of culture, the percentage of suppression for the untreated Treg lines
decreased to 55.2% ± 29.5% as compared to freshly isolated Tregs,
69.4% ± 19.3%, p = 0.025. However, Treg culture in the presence of
rapamycin conﬁrmed an increased Treg suppressive function,
80.5% ± 13.8%, as compared to untreated cultures, 55.2% ± 29.5%,
p = 0.0001.
One of the major concerns in Treg therapy is the reported plasticity
of these cells. It has been demonstrated that under inﬂammatory
conditions, human Tregs can adopt a Th17 phenotype, conferring
an undesirable pro-inﬂammatory phenotype and posing safetyar Therapy: Methods & Clinical Development Vol. 8 March 2018 201
A B
C D
Figure 4. Suppressive Ability and Plasticity of Freshly Isolated and Expanded Treg Lines
(A) Suppressive ability of Tregs was measured as a decrease of proliferation of effector T cells in the presence of different concentrations of Tregs (Treg:Teff 1:1, 1:5,
and 1:10). Graph denotes a representative suppression assay with freshly isolated Tregs before and after the 36-day expansion in the presence and absence of rapamycin.
(B) Cumulative data on the average suppressive ability of 25 Treg lines following isolation (fresh) and post expansion in the presence and absence of rapamycin at a Treg:Teff
ratio of 1:1. *p < 0.05; **p < 0.01; ***p < 0.001. Analysis of the plasticity and stability of the untreated or rapa-treated Treg lines after a 1-week culture in the presence of a pro-
inflammatory milieu. (C and D) Percentage of FOXP3+IL-17+ cells (C) and FOXP3+IFN-g+ cells (D) analyzed by intracellular staining. Data represent the mean ± SD of 3
independent experiments. Statistical analysis was performed using 1-way ANOVA, and where there was a significant difference, this is indicated. Control: IL-2 (10 IU/mL)
only; Cocktail A: IL-2, IL-1b, IL-6, and TGF-b; Cocktail B: IL-2, IL-21, IL-23, and TGF-b (see text for details).
Molecular Therapy: Methods & Clinical Developmentconcerns when used as a cell therapy product.30 To address this, at
ﬁnal harvest, Treg lines were stimulated with anti-CD3/CD28
beads and cultured in the presence of IL-17-inducing cytokines.
Two cytokine cocktails were selected: cocktail A, IL-1b, IL-2,
IL-6, and tumor growth factor beta (TGF-b); and cocktail B,
IL-2, IL-21, IL-23, and TGF-b. After 5 days of culture, the percent-
age of FOXP3+IL-17+ and FOXP3+IFN-g+ (interferon-gamma+)
cells was determined (Figures 4C and 4D). In comparison with un-
treated cultures, expansion in the presence of rapamycin resulted in
a decreased frequency of FOXP3+IL-17+ (cocktail A: untreated,
2.22% ± 1.27%, and rapamycin treated, 1.65% ± 0.70%; cocktail
B: untreated, 3.16% ± 2.09%, and rapamycin treated, 0.91% ±
0.36%) (Figures 4C and 4D). These results further conﬁrm our pre-
viously published work.24
Generation of Treg Lines for Clinical Use
Based on the requirement for GMP-compliant production of
advanced therapy medicinal products (ATMPs), necessitating202 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchreagents and consumables to be made in sterile environments,
we next sought to compare the effects of the different
reagents and of their combinations (Table 1) on Treg expansion
proﬁle, function, and stability during expansion. The use of
GMP-compliant materials did not alter the growth or characteris-
tics of Tregs presented so far using research-grade reagents (data
not shown) and, therefore, the components included in Table 1
(and marked with asterisks) were used for all future GMP
production.
As such, Figure 5 summarizes the optimal process developed, trans-
lating our preclinical work into a ﬁnely tuned GMP-compatible
expansion process. In brief, Tregs were stimulated with anti-CD3/
CD28 beads in a ratio of 4:1 (ExpAct Treg kit, Miltenyi Biotec) and
cultured in TexMACS GMP media (Miltenyi Biotec) supplemented
with 5% human serum (Lonza/Seralab). Rapamycin (Pﬁzer)
(100 nM) was added at the beginning of the culture, whereas IL-2
(Novartis) (500 IU/mL) was added after 4 days. Both rapamycin2018
Table 1. Optimization of Treg Expansion
Process
Tested
Reagent
Speciﬁcation of Tested
Reagent Titration Kinetics
Expansion
Cell
concentration
3x106
1x106
0.5x106*
anti-CD3/
CD28
beads
Invitrogen
1:2
1:1
2:1
4:1
Miltenyi Biotec
2:1
4:1*
IL-2 Proleukin - Novartis
500 IU/ml*
day 0
day 4*
day 6
1000 IU/ml
Rapamycin Rapamune - Pﬁzer
1nM
10nM
50nM
100nM*
Medium
Lonza - Xvivo
15 w phenol red
Lonza - Xvivo
15 w/o phenol red
Invitrogen - Optimizer
Miltenyi Biotec - TexMACS*
hAB serum
Biosera - research grade
2%
5%
Lonza - male hAB -
CE marked
5%*
Lonza – mixed hAB 5%
HSA 5%
Expansion
device
Plate
Flask
Expansion bags -
Miltenyi Biotec*
Bioreactor - Wilson Wolf
Asterisks (*) highlight the reagents used. Different combinations of reagents, in addi-
tion to varying titrations and kinetics, were used to devise a protocol for the optimal
expansion of Treg lines. Factors directly assessed consisted of Treg seeding concentra-
tions, bead:cell ratios (alongside comparison of anti-CD3- anti-CD28-coated beads
provided by different manufacturers), concentrations and timing of IL-2 supplemen-
tation, rapamycin concentrations, media from alternative manufacturers supple-
mented with various percentages of human serum or human serum albumin, expan-
sion devices, and cryopreservation media and vessels.
www.moleculartherapy.organd IL-2 were replenished every 2 to 3 days, and cells rested for 4 days
prior to restimulation. Cells were restimulated every 12 days by
adding activation beads, rapamycin, and IL-2. Phenotypic and func-
tional characterization of the Tregs was carried out following ﬁnal
harvest at day 36.MoleculEx Vivo-Expanded Tregs from Patients Yield an Enriched
Population, which Is Functionally Suppressive, Achieving the
Release Criteria Needed for Their Clinical Application
Having developed a clinically applicable GMP process for the isola-
tion and expansion of a pure and stable population of Tregs in the lab-
oratory, it was of importance to validate our process in the BRC GMP
Facility at Guy’s Hospital prior to the clinical application of Tregs.
Furthermore, in a previous publication,31 we presented an in-depth
characterization of Tregs isolated from patients with end-stage kidney
disease (ESKD), concluding that patients with ESKD have similar
numbers of Tregs as compared to the healthy donors. Here, we sought
to isolate Tregs using the CliniMACS Plus System and compared the
recovery of the isolated cells between the two patients with ESKD and
a healthy donor. Despite an initial lower recovery of isolated Tregs
from patients, 1 106 and 0.46 106, in comparison with the healthy
donor, 5  106, partly explained by the amount of the starting mate-
rial used, the expansion proﬁle was comparable with Tregs expanding
to numbers suitable for their clinical application (Figure 6A).
Characterization of the expanded Tregs was performed to ensure
that the ﬁnal product satisﬁed the speciﬁed release criteria in order
to allow their future clinical application. Flow cytometric
analysis of the Tregs at ﬁnal harvest established that the percentage
of CD4+CD25+FOXP3+ cells was 88.2% for the healthy donor and
74.7% and 76.7% for the patients (Figure S1). All ﬁnal products had
a viability of >95% and exhibited a potent suppressor function
of >80% in the classical suppression assay (Figure 6B). In addition,
contamination with CD8+ cells was minimal (<10% of CD8+ cells
in both groups) and all ﬁnal products passed the necessary safety tests
as deﬁned in the release criteria (Table 2).
Cryopreservation of Expanded Tregs
In order to allow infusion of the cell product 5 days post-transplant,
the feasibility of Treg cryopreservation was tested. Cryopreservation
of Tregs allows ﬂexibility in administration to assist with clinical
pathways and facilitates completion of all required release assays. In
addition, it allows time for transportation to different transplant cen-
ters, which would be important for ATMP trials involving centralized
manufacturing sites, such as Guy’s Hospital (London). For other tri-
als, cryopreservation could also allow for repeated dosing following
the production of a single Treg batch. Current experience with Treg
cryopreservation is limited. Published studies differ in freeze/thaw
techniques, either storing the isolated Tregs after leukapheresis
(weeks or months before transplantation32) or, as in the clinical trial
of Tregs isolated from umbilical cord blood (UCB), storing the cells
after ex vivo expansion.18
Choice of an appropriate process for cryopreservation of Tregs plays a
critical role in achieving a high recovery of fully functional Tregs after
cryopreservation. Various different factors have been studied, leading
to improvements in cryopreservation technique.33–37 The method
outlined in this manuscript resulted in a viability of >75% for both
the patient Treg cultures and healthy controls when cells were thawed
12 weeks after cryopreservation. In addition, total cell recovery wasar Therapy: Methods & Clinical Development Vol. 8 March 2018 203
Figure 5. Schematic Representation of the GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application
Blood is volume reduced using the Sepax 2 device (Biosafe) prior to Treg isolation. CD4+CD25+ T cells are isolated using a combination of CD8+ depletion (CD8 reagent,
Miltenyi Biotec) and enrichment step for CD25+ cells (CD25 reagent, Miltenyi Biotec) using the automated CliniMACS Plus System (Miltenyi Biotec). All processing steps are
performed in closed systems. Tregs are stimulated with anti-CD3/CD28 beads in a 4:1 ratio (ExpAct Treg kit, Miltenyi Biotec) and cultured in TexMACS GMPmedia (Miltenyi
Biotec) supplemented with 5% human serum (Lonza/Seralab). Rapamycin (Pfizer) (100 nM) is added at the beginning of the culture, whereas IL-2 (Novartis) (500 IU/mL) is
added after 4 days. Both rapamycin and IL-2 are replenished every 2 to 3 days, and cells are rested for 4 days prior to restimulation. Cells are restimulated every 12 days by
adding new activation beads, rapamycin, and IL-2. Phenotypic and functional characterization of the Tregs is carried out following final harvest at day 36 to ensure all final
products meet the specified release criteria prior to cryopreservation and subsequent clinical application.
Molecular Therapy: Methods & Clinical Developmentmore than 90% for both groups. Purity, assessed by intracellular
staining of FOXP3 as well as the surface markers CD4 and CD25,
averaged >70% for both groups, meeting the release criteria.
Importantly, the thawed cells maintained their suppressive function,
with >80% suppressive capability of Tregs from patients and healthy
donors (Table 2). These data show great promise for the clinical appli-
cation of cryopreserved Tregs.
DISCUSSION
Clinical trials to date have conﬁrmed the safety and hinted at the
efﬁcacy of Treg cell therapy in the context of bone marrow transplan-
tation18,19,21 and type I diabetes.20 Based on data from such studies,
there is a growing consensus that the therapeutic delivery of Tregs
has great promise for immunosuppressive drug minimization in the
ﬁeld of transplantation, with a component of the ONE study specif-
ically designed to investigate this rationale.
For Treg cell therapy to be a viable therapeutic option, the use of tailor-
made GMP-compliant isolation and expansion procedures is an
essential prerequisite. Organ transplant recipients demand a high pu-
rity of Tregs because infusion of non-regulatory cells into these pa-
tients may have the potential to intensify the disease process and/or
lead to graft damage. Therefore, it was important for us to monitor204 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchthe dynamics of Tregs throughout the isolation and expansion pro-
cess, ensuring that a phenotypically and functional stable population
of cells was manufactured for cell therapy application.
To this end, we sought to develop a protocol that ensured the efﬁcient
and reliable enrichment of functional humanCD4+CD25+ T cells from
healthy controls and patients with ESKD. The protocol that was devel-
oped (B) has nowbeen applied in the BRCGMP facility for the isolation
and expansion ofGMP-compliant Tregs frompatients with ESKD, and
Tregs manufactured according to this process have been administered
to twelve patients as part of theONE study (NCT02129881). Following
infusion, there have been no reports of toxicity or adverse events either
immediately or months after Treg administration, up to a dose of
10 106 Tregs/kg (personal communication).
In this manuscript, we have described the fundamental principles
required in the development of a Treg manufacturing process and
present our ﬁnal, reproducible strategy for the ex vivo expansion of
autologous patient-derived Tregs for clinical use.
Two different isolation strategies were directly compared, protocol
A and protocol B, concluding that an extra CD8 depletion step was
imperative in ensuring the isolation of a pure population of Tregs.2018
Figure 6. Expansion of Clinical Grade Tregs in the
BRC GMP Facility
Tregs isolated in accordance with GMP protocols from
two end-stage kidney disease patients and a healthy
control. (A) Comparable final harvest cell numbers
were observed between ESKD1 (117  106), ESKD2
(770  106), and the healthy control (303  106).
(B) Suppressive ability of Tregs was measured as a
decrease of proliferation of effector T cells in the presence
of different concentrations of Tregs (Treg:Teff 1:1, 1:5, and
1:10). Graph denotes a suppression assay, with
expanded Tregs after the 36-day expansion.
www.moleculartherapy.orgIFN-g producing CD8+ T cells have been shown to indicate a poor
outcome post-transplant; thus, these cells have to be excluded from
the initial isolated population in order to prevent their expansion in cul-
ture. Protocol B ensured that the percentage of CD8+ T cells was kept
<5%at the endof the 36-day cultureperiod, highlighting its comparative
merit.
Initially, Treg expansion processes were based purely on stimulation
with anti-CD3/anti-CD28 beads and concurrent supplementation
with recombinant IL-2.21 However, improvements in this process
have seen the use of rapamycin, shown to preferentially inhibit the
proliferation and function of CD25 conventional effector T cells,
thus permitting the preferential expansion of Tregs.23,38,39 In accor-
dance with this work, there is now a wealth of data from in vitro
and in vivo studies favoring the use of rapamycin for Treg induction,
expansion, and function.23,38–41
We further demonstrated that the use of rapamycin throughout the
culture was critical for the ex vivo selective expansion of a pure
(>75% FOXP3+) and highly suppressive (>80% at 1:1 ratio) popu-
lation of Tregs. Despite this promise, it has been reported that the
addition of rapamycin to Treg cultures diminishes overall Treg
expansion,23 which may require the extension of culture periods
in order to achieve therapeutic numbers. However, this solution
poses a challenge in itself, bearing in mind studies reporting a
loss of FOXP3 expression in human Tregs following prolonged cul-
ture.42 In this regard, we next compared the expansion proﬁles of
untreated and rapamycin-treated Treg lines throughout the 3
rounds of stimulations. In agreement with previous reports,24,43
at the ﬁrst round of stimulation, it was shown that the presence
of rapamycin decreased the expansion rate of Tregs as compared
to the untreated cultures (Figure 3C); however, this difference
decreased with subsequent rounds of stimulation. As such, the
data concluded that by ﬁnal harvest, the use of rapamycin did
not alter the expansion proﬁle of the Treg cultures as compared
to the untreated cultures, with 80% of the lines reaching numbers
suitable for clinical application.
Furthermore, in keeping with previous studies,26 the presence of ra-
pamycin in culture led to a higher expression of CD25 molecules
on Tregs while maintaining FOXP3 expression throughout the
36-day culture. Zeiser et al.39 provided an explanation for this ﬁnding,Moleculpostulating that inhibition of the mTOR pathway in the presence of
IL-2 allows Tregs to be constantly activated through the STAT-5
pathways, promoting their preferential expansion and preserved
FOXP3 expression. In accordance with these ﬁndings, we have incor-
porated more stringent release criteria to encompass FOXP3 expres-
sion. As such, the ﬁnal product needs to satisfy the release criteria,
withR60% of CD4+CD25+FOXP3+ cells.
One of the principles during Treg ex vivo expansion is to prevent the
induction and expansion of IL-17-producing cells. These inﬂamma-
tory cells have the potential to arise from T effectors contaminating
the Treg preparations44 and/or FOXP3+ Tregs converting to cells
producing pro-inﬂammatory cytokines.28 One major risk for Treg
therapy is that the cells may acquire effector functions and lose their
suppressive ability during inﬂammatory responses in vivo. To address
this issue, Treg lines were cultured in the presence of pro-inﬂamma-
tory cytokines previously reported to favor Th17 conversion.28,45
It was concluded that rapamycin decreased the percentage of FOXP3+
IL-17+, paralleled by a decrease in FOXP3+IFN-g+ cells, as compared
to untreated Treg lines (Figures 4C and 4D). This is consistent with
previous work by our group and others, demonstrating the inhibitory
effects of rapamycin on Th17 cells both in vitro and in vivo.24,46
The next stage in the development of the GMP-compliant cell prod-
uct involved the scale up process using 200 mL of blood from patients
with ESKD. The CliniMACS Plus system (Miltenyi Biotec) provided a
relatively versatile method for the GMP cell isolation, in which the
cells were separated on a clinical level in a closed and sterile system.
We have shown that Tregs from both patients and healthy donors can
be expanded after isolation using the CliniMACS System to
numbers needed for the maximum dose planned for the ONE study
(10  106/kg). Furthermore, the cells maintained their phenotype
and function throughout the 36-day culture period and fulﬁlled the
release criteria set for our clinical trials. As part of the ONE study,
we have further demonstrated the consistent manufacture of the ﬁnal
product, reaching numbers necessary for the planned doses, allowing
for the completion of the clinical trial.
Additionally, to improve logistics and allow infusion 5 days after kid-
ney transplantation, the data presented here also conclude that,
following the freeze/thaw process, Treg viability and suppressivear Therapy: Methods & Clinical Development Vol. 8 March 2018 205
Table 2. Characterization of GMP-Expanded Tregs before and after Cryopreservation
Test
Recipient Blood Healthy Control ESKD1 ESKD2
speciﬁcation ﬁnal harvest defrosting ﬁnal harvest defrosting ﬁnal harvest defrosting
Identity positive for CD4, CD25, and FOXP3 yes yes yes yes yes yes
Purity R60% of entire cell population CD4+CD25+FOXP3+ 88.2 71.7 74.7 70.5 76.7 88.6
Impurity %10% CD8+ 0.41 4.68 1.82 9.61 1.6 6.35
Viability R70% viability 96.5 76 96 93 95 82
Potency R60% suppression 81 97 83.1 84 91.3 95
Characterization of the expanded Tregs was performed to ensure the ﬁnal product satisﬁed the speciﬁed release criteria in order to allow their future clinical application. Release
criteria: (1) positive for CD4+CD25+FOXP3+; (2) CD4+CD25+FOXP3+ cells R60% of live cells; (3) CD8+ cells %10%; (4) viability R70%; and (5) suppression R60%. The two
ESKD patients and the healthy control met the speciﬁed release criteria before and after 12 weeks of cryopreservation in vapor phase liquid nitrogen.
Molecular Therapy: Methods & Clinical Developmentfunction was maintained. Furthermore, cryopreserving the ﬁnal
product allows more ﬂexibility around the timing of the infusion
and offers the possibility of administering multiple infusions in future
trials. However, current knowledge of how the process of cryopreser-
vation may affect Tregs is still limited. The data summarized in this
manuscript focuses on our ﬁndings 12 weeks after Treg cryopreserva-
tion, assessing the effects of the freeze/thaw process on the expanded
cells, with regard to their biology and function.
Growing interest in Tregs and enthusiasm for their potential clinical
applications have intensiﬁed over recent years based on encouraging
results laid down by early clinical trials. However, data concerning the
efﬁcacy of Treg cell therapy to date are limited. It is postulated that in
order to achieve maximal efﬁcacy, billions of expanded Tregs admin-
istered at multiple time points may be required. This possibility poses
further challenges for the preservation of a pure population of Tregs
following large-scale manufacture. Incorporation of new GMP isola-
tion techniques, such as a GMP-compatible FACS cell sorting that is
still under validation in Europe, offers the prospect of an attractive
solution to address this issue, paving the way for a bright future for
adoptive Treg immunotherapy.
MATERIALS AND METHODS
Cell Sources and Treg Separation and Expansion in the
Research Laboratory
In the laboratory, PBMCs from healthy donors were obtained from
anonymized human leukocyte cones supplied by the National Blood
Transfusion Service (NHS Blood and Transplantation, NHSBT, Toot-
ing, London, UK). Human studies were conducted in accordance with
the Declaration of Helsinki and approved by the Institutional Review
Board of Guy’s Hospital (reference 09/H0707/86 and 13/SC/0568).
PBMCs were isolated by lymphocyte (PAA, Pasching, Austria) den-
sity gradient centrifugation. CD4+CD25+T cells were separated using
either a single-step strategy involving CD25+ T cell enrichment
(protocol A) or a double-step procedure consisting of a CD8+ T cell
depletion step followed by enrichment of CD25+ T cells
(protocol B). All reagents and consumables used were of clinical
grade, including the magnetic-activated cell sorting (MACS) mi-
crobeads (CD8 reagent and CD25 reagent, Miltenyi Biotec, Woking,
UK) used in both processes.206 Molecular Therapy: Methods & Clinical Development Vol. 8 MarchFor development of the GMP-compliant Treg expansion process in
the research laboratory, human CD4+CD25+ T cells were plated at
1  106/mL in culture media X-vivo 15, with or without phenol red
(Lonza, Basel, Switzerland) OptMiser (Invitrogen, Paisley, UK) or
TexMACS GMPmedium (Miltenyi Biotech, Germany), supplemented
with 2%–5% human AB serum (HS) (Seralab, Ringer, UK; Lonza, UK)
or human serum albumin (Biotest, UK) containing rapamycin
(1–100 nM) (Rapamune, Wyeth/Pﬁzer, USA). Cells were activated
with Dynabeads CD3/CD28 CTS (Invitrogen, Paisley, UK) or ExpAct
Treg kit (Miltenyi Biotech, Germany) at deﬁned bead:cell ratios. IL-2
(500–1,000 IU/mL, Proleukin, Novartis, Frimley, UK) was added at
day 0–4 post-activation and replenished every 2 days. Cells were re-
stimulated every 10–12 days, with or without removing the activation
beads, adding fresh beads, rapamycin, and IL-2. Expanded cells were
used for further analysis at each restimulationuntil day 36of expansion.
Analysis of Cell Surface and Intracellular Markers to Confirm the
Identity of Freshly Isolated and Expanded Tregs
The following anti-human monoclonal antibodies (mAbs) were
used for ﬂow cytometry analysis: CD4-PerCP/Cy5.5 (clone OKT-4,
eBioscience); CD25-PE (clone 4E3; Miltenyi Biotec, Woking, UK);
CD62L-FITC (clone Greg-56; Invitrogen, Paisley, UK); CD8-APC
(clone RPA-T8), CD39-FITC (clone eBioA1), IFN-g-ﬂuorescein iso-
thiocyanate (FITC) (clone 4S.B3), IL17-PE (clone eBio64DEC17),
and FOXP3-FITC (clone PCH101), all from eBioscience (San Diego,
CA, USA); and CD27-PE (clone M-T271; BD Bioscience, Oxford,
UK). Prior to use, all mABs were titrated using normal resting or acti-
vated PBMCs to establish optimal staining dilutions.
After harvest, cells were washed and stained with the above listed
mAbs for 20 min at 4C. Intracellular staining for FOXP3 was per-
formed in accordance with themanufacturer’s protocol (eBioscience).
Appropriate isotype controls and ﬂuorescence minus one controls
were used to assign gates and ﬂow cytometry carried out on the
BD FACSCanto cell analyzer (BD Bioscience), and FlowJo software
used for subsequent data analysis.
Separation of Responder T Cells and Suppression Assays
Responder CD4+CD25 T cells were obtained from PBMCs by either
(1) negative selection using unconjugated anti-CD8, anti-CD33 (both2018
www.moleculartherapy.orgCaltag, CA, USA), anti-CD14, anti-CD16, anti-CD19, anti-CD56 (all
Diaclone, Gen-probe, San Diego, USA), anti-gd T cell receptor (TCR)
(clone B1.1), and glycophorin A (clone HIR-2) antibodies with pan-
immunoglobulin G (IgG) microbeads and anti-CD25 microbeads
(both Invitrogen, Paisley, UK) or (2) using the negative fraction ob-
tained from the miniMACS CD4+CD25+ T Regulatory Cell Isolation
Kit (Miltenyi Biotec, UK) as previously described.24 Aliquots of the
CD4+CD25 cells were cryopreserved and used as responder cells
in suppression assays.
Cryopreserved responder CD4+CD25 T cells (Teff) were thawed
and labeled with 2.5 mM CFSE (Molecular Probes, Carlsbad, CA,
USA). 1  105/well of responder T cells were co-cultured with Tregs
at different ratios (Treg:Teff 1:1, 1:5, and 1:10) in X-vivo 15 medium
supplemented with 5% HS and activated by anti-CD3/CD28-coated
beads (Invitrogen, Paisley, UK) in U-bottom 96-well plates. Cells
were incubated at 37C, 5% CO2, for 5 days. After harvest, prolifera-
tion of CFSE-labeled responder cells was acquired by ﬂow cytometry
(FACSCalibur or LSRFortessa cell analyzer [BD Bioscience]) and
analyzed with FlowJo software (Tree Star, OR, USA). The suppressive
ability of Treg lines was assessed as the percentage decrease of Teff
proliferation in the presence of Tregs. The calculation was based on
the proliferation of responder T cells alone compared with the prolif-
eration of cultures also containing Treg cells.Treg Culture in the Presence of Pro-inflammatory Cytokines
Freshly isolated, untreated, and rapamycin-treated CD4+CD25+
T cells (5  105) were activated with anti-CD3- and anti-CD28-
coated beads at a 1:1 bead:cell ratio and cultured for 5 days in the
presence of pro-inﬂammatory cytokine cocktails. Cocktail A: IL-2
(10 IU/mL), IL-1b (10 ng/mL, R&D Systems, Minneapolis, MN,
USA), IL-6 (4 ng/mL, R&D Systems, Minneapolis, MN, USA), and
TGF-b (5 ng/mL, R&D Systems, Minneapolis, MN, USA).
Cocktail B: IL-2 (10 IU/mL), IL-21 (25 ng/mL, Cell Sciences, Canton,
MA, USA), IL-23 (25 ng/mL, R&D Systems, Minneapolis, MN, USA),
and TGF-b (5 ng/mL, R&D Systems, Minneapolis, MN, USA). Cells
cultured in complete medium supplemented with IL-2 (10 IU/mL)
were used as controls to ensure their survival throughout the 5-day
stability assay. At the end of the culture, cells were harvested, activa-
tion beads were removed by magnetic adherence, and cells were
activated with phorbol myristate acetate (PMA) (5 ng/mL, Sigma-
Aldrich, St. Louis, MO, USA), ionomycin (1 mg/mL, Sigma-Aldrich,
St. Louis, MO, USA), and monensin (2 mM, eBioscience, San Diego,
CA, USA) for 4 hr. Subsequently, cells were analyzed for IL-17 and
IFN-g expression by intracellular staining.GMP-Compliant Treg Isolation, Expansion, and
Cryopreservation in the BRC GMP Facility
Isolation
For the GMP validation of the process, a buffy coat was obtained from
NHSBT and used as a healthy donor, whereas 200 mL of blood was
obtained from two patients with ESKD on hemodialysis (inclusion/
exclusion criteria as per the ONE study, NCT02129881). Patient de-Moleculmographics are outlined in Table S1. Informed consent was obtained
from all donors prior to enrolment into the study.
Blood volume was reduced using the Sepax 2 device (Biosafe) prior to
Treg isolation. CD4+CD25+ T cells were isolated using a combination
of CD8+ depletion (CD8 reagent, Miltenyi Biotec) and enrichment
step for CD25+ cells (CD25 reagent, Miltenyi Biotec) using the auto-
mated CliniMACS Plus System (Miltenyi Biotec) in the BRC GMP
Facility at Guy’s Hospital. All processing steps were performed in
closed systems. Human studies were conducted in accordance with
the Declaration of Helsinki and approved by the Institutional Review
Board of Guy’s Hospital (reference 09/H0707/86).
Expansion
In the BRC GMP Facility, cells were seeded in MACS GMP Cell
Differentiation/Expansion Bags at 0.5  106 cells/mL in TexMACS
GMP Medium (Miltenyi Biotec, Germany), supplemented with 5%
human serum containing 100 nM rapamycin (Rapamune) and
activated with anti-CD3- and anti-CD28-coated beads (4:1
bead:cell ratio, MACS GMP ExpAct Treg Kit, Miltenyi Biotec,
Germany). Human recombinant IL-2 (500 IU/mL; Proleukin)
was added at day 4–6 and replenished every 2 to 3 days. The cells
were rested for 4 days before restimulation. Stimulation occurred
on days 12 and 24, during which time cells were pooled, fresh
beads (1:1), rapamycin and IL-2 were added, and the suspension
was re-seeded at 0.5  106 cells/mL into new bags (250, 500, or
1,000 mL) For a schematic representation of the process see
Figure 5. Expanded cells were harvested on day 36 and pooled.
The ExpAct Treg expansion beads were depleted using the
CliniMACS Plus System (Miltenyi Biotec) to form a bead-depleted
cell population. A small aliquot of the cells was then taken for
safety and functional analysis.
Cryopreservation
Because the ONE study is a multi-site trial, cryopreservation of the
Tregs is required to accommodate for the transfer of these cells to
different trial sites. In addition, the cryopreservation of Tregs allows
the storage and dosing of patients to occur at speciﬁed dates in rela-
tion to transplantation (5 days after transplantation in the ONE
study) and can prevent any issues that may occur due to unforeseen
circumstances, which could alter transplantion dates.
After ﬁnal harvest, all batches had to fulﬁll the set release
criteria that included (1) CD4+CD25+FOXP3+ cells R60% of the
live cell population; (2) CD8+ cells %10%; (3) %100 beads per
3  106 cells; (4) viability R70%; (5) sterility: no growth after
5 days (BacT/ALERT, Biomerieux); (6) endotoxin %175 IU/mL;
(7) mycoplasma: not detected; and (8) suppressionR60%. For cryo-
preservation, cells were pelleted by centrifugation and resuspended
in CryoStor CS10 freezing media at a concentration to provide
the dose of cells required in 2 mL. The product was transferred
into CellSeal Cryovials, 2.1 mL per vial, and cooled to 80C in a
controlled rate freezer before transfer to liquid nitrogen (vapor
phase) for long-term storage.ar Therapy: Methods & Clinical Development Vol. 8 March 2018 207
Molecular Therapy: Methods & Clinical DevelopmentIn order to assess the stability of the cryopreserved product and the
effect of cryopreservation on the biology and function of the ﬁnal
product, cells were thawed rapidly and diluted in 5% human serum
albumin, and the viability, recovery, phenotype, and suppressive
function of the cryopreserved product were assessed.
Statistical Analysis
Statistical analysis was carried out on GraphPad Prism 5.0c
(GraphPad software, CA, USA). Parametric and nonparametric
data were expressed as mean ± standard error and median, where
appropriate. For comparison of parametric data, paired and unpaired
Student’s t tests (for two samples) and 1-way ANOVA (for multiple
comparisons) were carried out as appropriate. Statistical signiﬁcance
was set at p < 0.05. *p < 0.05, ** p < 0.01, and *** p < 0.001.
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